Addus HomeCare (NASDAQ:ADUS) CEO Sells $249,071.04 in Stock

Addus HomeCare Corporation (NASDAQ:ADUS) CEO R Dirk Allison sold 2,364 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $105.36, for a total transaction of $249,071.04. Following the completion of the sale, the chief executive officer owned 183,150 shares of the company’s stock, valued at $19,296,684. This trade represents a 1.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

R Dirk Allison also recently made the following trade(s):

• On Tuesday, February 24th, R Dirk Allison sold 4,988 shares of Addus HomeCare stock. The stock was sold at an average price of $106.98, for a total value of $533,616.24.

Addus HomeCare Stock Performance

NASDAQ:ADUS traded down $3.58 on Thursday, hitting $104.02. The company’s stock had a trading volume of 269,378 shares, compared to its average volume of 239,147. Addus HomeCare Corporation has a one year low of $88.96 and a one year high of $124.43. The firm has a market capitalization of $1.92 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 1.26 and a beta of 0.91. The stock has a fifty day moving average of $109.57 and a two-hundred day moving average of $113.08. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.11.

Analysts Set New Price Targets

Several research firms have commented on ADUS. Truist Financial set a $135.00 price objective on shares of Addus HomeCare and gave the company a “buy” rating in a report on Wednesday, January 7th. BMO Capital Markets began coverage on shares of Addus HomeCare in a report on Thursday, November 13th. They set a “market perform” rating and a $120.00 target price for the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $139.00 price target on shares of Addus HomeCare in a research note on Wednesday. KeyCorp restated an “overweight” rating on shares of Addus HomeCare in a research report on Wednesday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Addus HomeCare in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $134.33.

Hedge Funds Weigh In On Addus HomeCare

A number of hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC boosted its holdings in Addus HomeCare by 395.7% in the 4th quarter. Global Retirement Partners LLC now owns 233 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the period. Larson Financial Group LLC increased its holdings in shares of Addus HomeCare by 133.3% during the third quarter. Larson Financial Group LLC now owns 238 shares of the company’s stock worth $28,000 after purchasing an additional 136 shares during the period. Acumen Wealth Advisors LLC acquired a new stake in shares of Addus HomeCare in the fourth quarter valued at approximately $29,000. Private Trust Co. NA boosted its stake in shares of Addus HomeCare by 65.5% in the fourth quarter. Private Trust Co. NA now owns 283 shares of the company’s stock valued at $30,000 after buying an additional 112 shares during the period. Finally, Arax Advisory Partners boosted its stake in shares of Addus HomeCare by 95.8% in the fourth quarter. Arax Advisory Partners now owns 280 shares of the company’s stock valued at $30,000 after buying an additional 137 shares during the period. 95.35% of the stock is owned by institutional investors.

Addus HomeCare News Roundup

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: Q4 earnings/earnings call emphasized continued revenue growth, margin-leverage opportunities and an M&A-driven growth strategy for 2026 — supports longer‑term earnings upside. Addus HomeCare Earnings Call Highlights Growth And Scale
• Positive Sentiment: Stephens trimmed its price target from $140 to $135 but kept an “overweight” rating — the new target implies meaningful upside from current levels, indicating analyst confidence in the company’s outlook despite the cut. Stephens price target note
• Neutral Sentiment: Addus will participate in the Raymond James Institutional Investors Conference (investor visibility event; typically neutral but can aid liquidity/coverage). Conference participation
• Neutral Sentiment: Some published short‑interest data in the feed shows zero shares (data glitch/inconsistent reporting across sources) — treat those specific zero figures with caution. MarketBeat ADUS page
• Negative Sentiment: Significant insider selling over Feb. 24–25: CEO R. Dirk Allison sold two blocks (4,988 and 2,364 shares) and multiple senior EVPs sold smaller blocks across the two days — coordinated insider sales can pressure sentiment even if individual sales are routine and pre‑planned. See CEO filing. CEO insider-sale SEC filing
• Negative Sentiment: Short interest rose earlier in February (as of Feb. 13 there were ~1.15M shares short, ~6.5% of shares outstanding and ~4.6 days‑to‑cover) — elevated short activity can amplify downward price moves. Short interest data

About Addus HomeCare

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.